Why the study?
Does recombinant von Willebrand factor fragment VCL inhibit platelet aggregation and adhesion compared to peptides 153 and 154 in vitro?
Population
In vitro models of platelet aggregation and adhesion
Comparison
Recombinant von Willebrand factor fragment VCL vs Peptides 153 and 154
Design
Preclinical
Authors
Loading...
VCL's potent in vitro antiplatelet activity supports preclinical antithrombotic development; leaves open clinical translation and safety.
Does recombinant von Willebrand factor fragment VCL inhibit platelet aggregation and adhesion compared to peptides 153 and 154 in vitro?
The recombinant von Willebrand factor fragment VCL potently inhibits platelet adhesion and aggregation at high shear forces, suggesting potential as an antithrombotic agent.
Gralnick et al. (1992) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: